{"nct_id":"NCT02663622","title":"Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)","status":"COMPLETED","status_verified_date":"2024-01","start_date":"2016-09-19","start_date_type":"ACTUAL","primary_completion_date":"2020-06-08","primary_completion_date_type":"ACTUAL","completion_date":"2021-05-18","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["MRK"]}